The dates and location of the 2015 Trans-Pacific Health Sciences Dialogue will be announced soon.

See you in Boston

Take a look at some photos from the 2014 Trans-Pacific Health Sciences Dialogue!

Day 1 PhotosDay 2 Photos

About the Conference

The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.





Who Should Attend


The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.

Industry News from BioCentury

  • Kolltan withdraws IPOCancer play Kolltan Pharmaceuticals Inc. (New Haven, Conn.) withdrew its proposed IPO on NASDAQ. The company did not provide a reason in its SEC filing and did not respond to inquiries. In September, Kolltan filed to raise up to $86.3 million in an offering underwritten by Leerink Partners; Stifel; Guggenheim Securities; and Janney Montgomery Scott.

    Last month, Kolltan said it expected to report data this half from its Phase Ib trial of KTN3379, a human mAb against epidermal growth factor receptor 3 (EGFR3; HER3; ErbB3), to treat advanced solid tumors.
Read more

Industry News from PharmAsia

  • China’s Healthcare Sector Set for Foreign Investment ExplosionForeign Direct Investment (FDI) into China's life sciences sector will increase by 177% to £128.2 billion by 2020, as the rapidly ageing population drives demand for healthcare services and the Chinese government makes efforts to relax controls. So says a new report from global law firm King & Wood Mallesons, Branching Out: Investment Opportunities in China in 2020.
Read more

Upcoming Supporter Events


Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel
Philadelphia, PA

Read more